Aastrom Shares Get Jolt from Cash Infusion (ASTM)

March 9, 2012 by Paul Ausick

Aastrom Biosciences Inc. (NASDAQ: ASTM) announced today a $40 million private placement of Series B convertible preferred stock with Eastern Capital Ltd. The company expects to receive net proceeds of about $38 million and plans to use the funds for general corporate purposes and to support “research and development expenses related to the pivotal Phase 3 REVIVE-CLI clinical trial with ixmyelocel-T initiated in February 2012.” The drug is being developed to treat critical limb ischemia and ischemic dilated cardiomyopathy.

Under the terms of the placement:

Aastrom issued approximately 12,300 shares of Series B convertible preferred stock to Eastern Capital at a price of $3,250 per share. The shares will accrue dividends at a rate of 11.5% per annum during the 5-year term. The Series B preferred stock is convertible into shares of the Company’s common stock only after March 8, 2017 at a rate of 1,000 common shares for one preferred share. There were no warrants issued in connection with the financing and Eastern Capital will not take a board seat.

The deal appears to be a good one for Aastrom and for its shareholders. The conversion price is near the company’s 52-week high of $3.47 and gives Aastrom time to complete its trials (and boost its stock price) before the conversion clause becomes effective.

Shares are currently up nearly 24% at $2.25 in a 52-week range of $1.75-$3.47.

Sponsored: Want to Retire Early? Here’s a Great First Step

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.